Developer docs
API playgroundTry for free, no card

Search company profiles

Ribometrix

Full company profile

uuid0000qlv

Namestring
Ribometrix
Legal namestring
Ribometrix Inc.
Websiteurl
ribometrix.com
Company typeenum
Private
Founded yearint
2016
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersDurham, United States
HQ citystring
Durham
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
RNA-targeting drug discovery, small molecule therapeutics, preclinical oncology drug discovery, RNA structural biology, pharmaceutical partnership platform
Industry4 codes
PRIMARYHLAAADAG
RNA Therapeutics Platforms & Design (sequence design, target ID/validation, AI/bioinformatics)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAADAE
RNA Chemistry & Oligonucleotide Engineering (backbones, modifications, stereochemistry)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAADAH
RNA Therapeutics Clinical Development (trial design, endpoints, patient stratification)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAADAF
RNA Manufacturing & CMC (oligo synthesis, IVT, purification, formulation, QC)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Preclinical RNA-Targeting Drug Discovery
Social media profiles3 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Strategic Partnership Payments
TypeLicensing Royalties
Description

Ribometrix generates revenue through strategic partnerships with pharmaceutical companies. These arrangements include upfront payments, research funding, milestone payments tied to development and regulatory achievements, and tiered royalties on net sales of any resulting products. The Vertex collaboration provides approximately $20 million upfront plus potential $700M+ in milestones and royalties. The Genentech collaboration provides $25 million upfront with potential milestones exceeding $1 billion.

ribometrix.com
2Internal Pipeline Development
TypeLicensing Royalties
Description

The company is advancing wholly-owned programs including eIF4E and c-MYC targeting cancer indications. These programs aim to develop novel therapeutics that would be commercialized either independently or through future partnership arrangements upon achievement of clinical milestones.

ribometrix.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Ribometrix is a preclinical platform therapeutics company that discovers and develops small molecule drugs which directly target cellular RNAs to modulate the production of disease-causing proteins. The company applies its proprietary 3D RNA structural analysis platform (SHAPE-MaP, RING-MaP) to identify druggable RNA structural hotspots and to discover small molecules that bind and selectively modulate these targets. Internal pipeline programs focus on oncology targets eIF4E and c-MYC, while external programs are advanced through strategic partnerships with major pharmaceutical companies.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • RBX-6610 monotherapy caused 75% vs 71% TGI in treatment-naïve and resistant KRASG12C NSCLC xenograft models respectively
+2 more records
Product overview1 text field

Ribometrix is a preclinical biotechnology company with a best-in-class platform for discovering and developing small molecule therapeutics that selectively bind and modulate cellular mRNAs to correct disease-causing protein expression. The company's core platform combines three main capabilities: (1) Rational Target Prioritization (RTP) for identifying druggable RNA structures, (2) RNA Modulation Through Binding Alone for discovering functional RNA binders, and (3) BOLSTR™ technology for engineering RNA-degrading functions into silent binders. The proprietary platform is applied across internal pipeline programs including the eIF4E inhibitor program (lead program RBX-6610) targeting multiple cancer indications, and the c-MYC mRNA-targeting program. Strategic collaborations with Genentech and Vertex leverage the discovery platform for additional therapeutic programs.

Product and service3 records
1RBX-6610 eIF4E Inhibitor
CategoryRNA-Targeting Small Molecule Therapeutic (Lead Program)
Description

Lead small molecule inhibitor of eukaryotic translation initiation factor 4E (eIF4E) being developed for the treatment of KRASG12C mutant non-small cell lung cancer (NSCLC), designed to re-sensitize tumors resistant to KRAS inhibitors when used in combination therapy. RBX-6610 has demonstrated anti-proliferative effects and synergistic apoptotic induction when combined with KRAS inhibitors in KRASG12C mutant NSCLC xenograft models.

2eIF4E Inhibitor Program
CategoryRNA-Targeting Small Molecule Therapeutic Program
Description

Internal program developing small molecule inhibitors targeting the eukaryotic translation initiation factor 4E (eIF4E) RNA-binding protein for cancer treatment, with applications across melanoma, breast cancer, NSCLC, and colorectal cancer. IND filing planned for first half of 2025 with non-GLP toxicology studies completed and IND-enabling studies underway.

3c-MYC mRNA-Targeting Program
CategoryRNA-Targeting Small Molecule Therapeutic Program
Description

Program developing small molecules that directly bind oncogenic c-MYC mRNA to reduce c-MYC protein expression, addressing a historically undruggable cancer target dysregulated in more than 70% of cancers through RNA targeting. Demonstrates direct binding of small molecules to c-MYC RNA and reduction of associated protein levels.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2021-01-06
Description

Exclusive worldwide license and collaboration agreement to discover, develop and commercialize small molecule drug candidates against several RNA targets. Ribometrix receives $25 million upfront payment and is eligible for potential milestone payments exceeding $1 billion, plus tiered royalties on future global net sales. Genentech is responsible for development and commercialization following discovery and preclinical development phases.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2019-09-30
Description

Strategic collaboration to discover and develop novel RNA-targeted small molecule therapeutic candidates for serious diseases. Partnership combines Ribometrix's discovery platform with Vertex's scientific, clinical and regulatory capabilities for up to three therapeutic programs. Ribometrix receives $20 million upfront (including equity investment) with potential for more than $700 million in milestone payments and tiered royalties. Vertex has option to take exclusive global license for each program.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

Develops small molecule read-through agents that target ribosome-RNA interactions for rare diseases. Adjacent to Ribometrix's RNA-targeting approach, demonstrating both the opportunity and challenges of small molecule RNA-targeting therapeutics.

TypeDirect peer
Description

Develops small molecule therapeutics targeting RNA-modifying proteins for cancer. Comparable to Ribometrix in preclinical-to-clinical-stage RNA-targeted oncology pipeline and partnership-driven model (Lexicon partnership).

TypeDirect peer
Description

Direct competitor developing small molecule drugs that bind RNA structures, with a focus on previously undruggable targets. Closely comparable to Ribometrix in modality (RNA-targeting small molecules), platform approach, and therapeutic focus on oncology and other diseases.

TypeDirect peer
Description

Develops small molecules that target RNA splicing for neurological diseases and oncology. Directly comparable to Ribometrix in RNA-targeting small molecule modality and partnership-driven business model, with multiple major pharma collaborations.

TypeEmerging player
Description

Focused on RNA biology and adaptive stress response in cancer. Comparable in leveraging RNA biology for oncology drug discovery, though with a distinct biological angle (stress response pathways) rather than direct RNA structural targeting.

TypeEmerging player
Description

RNA-based therapeutics company where Ribometrix's new CEO William Marshall previously served as President and CEO. Comparable in RNA therapeutics modality focus and leadership lineage, providing a benchmark for development trajectories in RNA drug discovery.

7Expansion Therapeutics
TypeDirect peer
Description

Pursues small molecule therapeutics targeting RNA-repeat expansion disorders. Comparable in small molecule RNA-targeting approach and preclinical stage, though focused on neurological repeat expansion diseases rather than oncology.

TypeDirect peer
Description

Uses REM-seq platform to identify small molecules that modulate RNA processing. Closely comparable to Ribometrix's approach of using RNA biology to discover small molecule therapeutics, with overlapping oncology focus and similar partnership-driven strategy.

TypeDirect peer
Description

Targets RNA-modifying proteins (particularly METTL3) with small molecules for cancer. Comparable in combining RNA biology insights with small molecule drug discovery, with a focus on oncology similar to Ribometrix's eIF4E and c-MYC programs.

TypeDirect peer
Description

Pioneer in RNA epitranscriptomics with small molecule inhibitors targeting RNA-modifying enzymes. Comparable in RNA-focused small molecule discovery for oncology, though with a distinct mechanistic angle (epitranscriptomics rather than direct RNA binding).

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles13 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors10 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Ribometrix

Preclinical RNA-Targeting Drug Discoveryribometrix.com

Ribometrix firmographics

Firmographics
Name
Ribometrix
Legal name
Ribometrix Inc.
Website
https://ribometrix.com
Company type
Private
Founded year
2016
Operating status
Operating
Headcount range
11–50 employees
Ownership category
akta.pro rank

Ribometrix industry classification

Industry
Product category
Preclinical RNA-Targeting Drug Discovery
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAAADAG
RNA Therapeutics Platforms & Design (sequence design, target ID/validation, AI/bioinformatics)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAADAE
RNA Chemistry & Oligonucleotide Engineering (backbones, modifications, stereochemistry)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAADAH
RNA Therapeutics Clinical Development (trial design, endpoints, patient stratification)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAADAF
RNA Manufacturing & CMC (oligo synthesis, IVT, purification, formulation, QC)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)

Keywords

  • RNA-targeting drug discovery
  • Small molecule therapeutics
  • Preclinical oncology drug discovery
  • RNA structural biology
  • Pharmaceutical partnership platform

Where Ribometrix is headquartered

Location

Headquarters

HQ city
Durham
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Ribometrix business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Infrastructure

Revenue model

  1. Strategic Partnership Payments: Ribometrix generates revenue through strategic partnerships with pharmaceutical companies. These arrangements include upfront payments, research funding, milestone payments tied to development and regulatory achievements, and tiered royalties on net sales of any resulting products. The Vertex collaboration provides approximately $20 million upfront plus potential $700M+ in milestones and royalties. The Genentech collaboration provides $25 million upfront with potential milestones exceeding $1 billion.
  2. Internal Pipeline Development: The company is advancing wholly-owned programs including eIF4E and c-MYC targeting cancer indications. These programs aim to develop novel therapeutics that would be commercialized either independently or through future partnership arrangements upon achievement of clinical milestones.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

Ribometrix product offering

Product offering

Core offering

Ribometrix is a preclinical platform therapeutics company that discovers and develops small molecule drugs which directly target cellular RNAs to modulate the production of disease-causing proteins. The company applies its proprietary 3D RNA structural analysis platform (SHAPE-MaP, RING-MaP) to identify druggable RNA structural hotspots and to discover small molecules that bind and selectively modulate these targets. Internal pipeline programs focus on oncology targets eIF4E and c-MYC, while external programs are advanced through strategic partnerships with major pharmaceutical companies.

Product overview

Ribometrix is a preclinical biotechnology company with a best-in-class platform for discovering and developing small molecule therapeutics that selectively bind and modulate cellular mRNAs to correct disease-causing protein expression. The company's core platform combines three main capabilities: (1) Rational Target Prioritization (RTP) for identifying druggable RNA structures, (2) RNA Modulation Through Binding Alone for discovering functional RNA binders, and (3) BOLSTR™ technology for engineering RNA-degrading functions into silent binders. The proprietary platform is applied across internal pipeline programs including the eIF4E inhibitor program (lead program RBX-6610) targeting multiple cancer indications, and the c-MYC mRNA-targeting program. Strategic collaborations with Genentech and Vertex leverage the discovery platform for additional therapeutic programs.

Differentiator

Problem solved

Functional benefit

Products and services

  • RBX-6610 eIF4E Inhibitor Lead small molecule inhibitor of eukaryotic translation initiation factor 4E (eIF4E) being developed for the treatment of KRASG12C mutant non-small cell lung cancer (NSCLC), designed to re-sensitize tumors resistant to KRAS inhibitors when used in combination therapy. RBX-6610 has demonstrated anti-proliferative effects and synergistic apoptotic induction when combined with KRAS inhibitors in KRASG12C mutant NSCLC xenograft models.
  • eIF4E Inhibitor Program Internal program developing small molecule inhibitors targeting the eukaryotic translation initiation factor 4E (eIF4E) RNA-binding protein for cancer treatment, with applications across melanoma, breast cancer, NSCLC, and colorectal cancer. IND filing planned for first half of 2025 with non-GLP toxicology studies completed and IND-enabling studies underway.
  • c-MYC mRNA-Targeting Program Program developing small molecules that directly bind oncogenic c-MYC mRNA to reduce c-MYC protein expression, addressing a historically undruggable cancer target dysregulated in more than 70% of cancers through RNA targeting. Demonstrates direct binding of small molecules to c-MYC RNA and reduction of associated protein levels.

Quantifiable outcome

  • RBX-6610 monotherapy caused 75% vs 71% TGI in treatment-naïve and resistant KRASG12C NSCLC xenograft models respectively
  • +2 more outcomes

Companies that use Ribometrix

Customer profile

Segments2 records

Ideal customer profiles1 record

Ribometrix technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Ribometrix partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered flagship and core.

  • Genentech (Roche Group)flagshipStrategic or Co-development Partner · 6 January 2021Exclusive worldwide license and collaboration agreement to discover, develop and commercialize small molecule drug candidates against several RNA targets. Ribometrix receives $25 million upfront payment and is eligible for potential milestone payments exceeding $1 billion, plus tiered royalties on future global net sales. Genentech is responsible for development and commercialization following discovery and preclinical development phases.
  • Vertex PharmaceuticalscoreStrategic or Co-development Partner · 30 September 2019Strategic collaboration to discover and develop novel RNA-targeted small molecule therapeutic candidates for serious diseases. Partnership combines Ribometrix's discovery platform with Vertex's scientific, clinical and regulatory capabilities for up to three therapeutic programs. Ribometrix receives $20 million upfront (including equity investment) with potential for more than $700 million in milestone payments and tiered royalties. Vertex has option to take exclusive global license for each program.

Scale indicators7 records

Recent moves7 records

Expansion highlights6 records

Ribometrix competitors and assessment

Company assessment

Emerging players

  • Eloxx Pharmaceuticals: Develops small molecule read-through agents that target ribosome-RNA interactions for rare diseases. Adjacent to Ribometrix's RNA-targeting approach, demonstrating both the opportunity and challenges of small molecule RNA-targeting therapeutics.
  • HiberCell: Focused on RNA biology and adaptive stress response in cancer. Comparable in leveraging RNA biology for oncology drug discovery, though with a distinct biological angle (stress response pathways) rather than direct RNA structural targeting.
  • MiRagen Therapeutics (now Viridian Therapeutics): RNA-based therapeutics company where Ribometrix's new CEO William Marshall previously served as President and CEO. Comparable in RNA therapeutics modality focus and leadership lineage, providing a benchmark for development trajectories in RNA drug discovery.

Direct peers

  • Accent Therapeutics: Develops small molecule therapeutics targeting RNA-modifying proteins for cancer. Comparable to Ribometrix in preclinical-to-clinical-stage RNA-targeted oncology pipeline and partnership-driven model (Lexicon partnership).
  • Arrakis Therapeutics: Direct competitor developing small molecule drugs that bind RNA structures, with a focus on previously undruggable targets. Closely comparable to Ribometrix in modality (RNA-targeting small molecules), platform approach, and therapeutic focus on oncology and other diseases.
  • Skyhawk Therapeutics: Develops small molecules that target RNA splicing for neurological diseases and oncology. Directly comparable to Ribometrix in RNA-targeting small molecule modality and partnership-driven business model, with multiple major pharma collaborations.
  • Expansion Therapeutics: Pursues small molecule therapeutics targeting RNA-repeat expansion disorders. Comparable in small molecule RNA-targeting approach and preclinical stage, though focused on neurological repeat expansion diseases rather than oncology.
  • Remix Therapeutics: Uses REM-seq platform to identify small molecules that modulate RNA processing. Closely comparable to Ribometrix's approach of using RNA biology to discover small molecule therapeutics, with overlapping oncology focus and similar partnership-driven strategy.
  • Twentyeight-Seven Therapeutics: Targets RNA-modifying proteins (particularly METTL3) with small molecules for cancer. Comparable in combining RNA biology insights with small molecule drug discovery, with a focus on oncology similar to Ribometrix's eIF4E and c-MYC programs.
  • Storm Therapeutics: Pioneer in RNA epitranscriptomics with small molecule inhibitors targeting RNA-modifying enzymes. Comparable in RNA-focused small molecule discovery for oncology, though with a distinct mechanistic angle (epitranscriptomics rather than direct RNA binding).

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Ribometrix social profiles

Digital presence

Ribometrix financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Ribometrix leadership team

Management profile

Number of profiles

Profiles13 records

Ribometrix funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors10 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Ribometrix M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Ribometrix

What does Ribometrix do?

Ribometrix is a preclinical platform therapeutics company that discovers and develops small molecule drugs which directly target cellular RNAs to modulate the production of disease-causing proteins. The company applies its proprietary 3D RNA structural analysis platform (SHAPE-MaP, RING-MaP) to identify druggable RNA structural hotspots and to discover small molecules that bind and selectively modulate these targets. Internal pipeline programs focus on oncology targets eIF4E and c-MYC, while external programs are advanced through strategic partnerships with major pharmaceutical companies.

Is Ribometrix a public or private company?

Ribometrix is a private company. It is classified as venture growth investor backed and is currently operating.

When was Ribometrix founded?

Ribometrix was founded in 2016. It employs 11 to 50 people.

Where is Ribometrix based?

Ribometrix is headquartered in Durham, United States, in the North America region.

How does Ribometrix make money?

Two revenue lines are on record. Strategic Partnership Payments are the primary driver. The others are internal Pipeline Development.

Who are Ribometrix's main competitors?

Emerging players on record are Eloxx Pharmaceuticals, HiberCell and MiRagen Therapeutics (now Viridian Therapeutics). Direct peers are Accent Therapeutics, Arrakis Therapeutics, Skyhawk Therapeutics, Expansion Therapeutics, Remix Therapeutics, Twentyeight-Seven Therapeutics and Storm Therapeutics.

Does Ribometrix have an API?

No public API is recorded for Ribometrix.

What industry is Ribometrix in?

Ribometrix's product category is Preclinical RNA-Targeting Drug Discovery. Its primary akta.pro industry code is HLAAADAG, RNA Therapeutics Platforms & Design (sequence design, target ID/validation, AI/bioinformatics), with a secondary code of HLAAADAE, RNA Chemistry & Oligonucleotide Engineering (backbones, modifications, stereochemistry). Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
BioWorldRibometrix in potential $1B-plus Roche deal as more enter RNA foldRibometrix Inc. has entered into a potential deal valued at over $1 billion with Roche Holding AG's Genentech arm to discover and develop RNA-targeted small-molecule therapeutics. The agreement includes an upfront payment of $25 million for Genentech, which gains exclusive global rights to several predefined targets. This transaction highlights the growing interest from major pharmaceutical companies in RNA-focused drug discovery.Flagler Business SchoolKevin Weeks named Senior Member of National Academy of InventorsKevin Weeks, a Distinguished Professor of Chemistry at UNC-Chapel Hill, has been recognized as a Senior Member of the National Academy of Inventors for his contributions to RNA research and its applications in medicine. His co-founded companies, Ribometrix and ForagR Medicines, are working to transform scientific breakthroughs into therapies for previously untreatable diseases. Weeks emphasizes the importance of simple technology in drug discovery and the potential for RNA-targeted drugs to revolutionize treatment options.Business Wire BlogRibometrix to Present New Preclinical Data From RNA-Modulating Small Molecule Programs Targeting eIF4E and c-MYC at the 2024 AACR Annual MeetingRibometrix will present two posters at the 2024 AACR Annual Meeting on preclinical data for its RNA-modulating small molecules targeting eIF4E and c-MYC. The eIF4E data show in vivo tumor regression across multiple indications, and the c-MYC data demonstrate small molecules binding c-MYC mRNA and reducing protein levels.BioSpaceRibometrix Promotes Dr. Manjunath Ramarao to Chief Scientific OfficerRibometrix, Inc. promoted Dr. Manjunath Ramarao to Chief Scientific Officer to lead its platform and pipeline of small molecule drugs targeting RNA, succeeding the retired John Reardon. Dr. Ramarao brings extensive experience from previous roles at Biocon-Bristol-Myers Squibb and Pfizer to guide the company's R&D capabilities. The announcement highlights Ribometrix's ongoing collaborations with Genentech and Vertex Pharmaceuticals.BioPharma DiveRoche adds to RNA drug deal streak with Ribometrix partnershipRoche has partnered with Ribometrix to develop chemical-based drugs targeting RNA molecules, announcing the deal on Wednesday. Roche will pay Ribometrix $25 million upfront, with potential total payments exceeding $1 billion based on milestone achievements. This collaboration is part of Roche's strategy to invest in innovative approaches to drug development, particularly focusing on previously deemed 'undruggable' targets.STATVertex takes on Huntington’s disease in deal with RibometrixVertex Pharmaceuticals has entered into a deal with Ribometrix to develop RNA-targeted medicines for serious illnesses, including Huntington's disease. Vertex will pay Ribometrix $20 million upfront to support the discovery and development of at least two such drugs, with an option for a third. This partnership reflects Vertex's efforts to expand its portfolio beyond its well-known cystic fibrosis treatments.FinSMEsRibometrix Raises $7.8M in FundingRibometrix, a Durham, N.C.-based biotechnology company, raised $7.8M in funding from existing investors. The company will use the funds to develop its discovery platform, and Mike Clayman, M.D., was appointed chairman of the board.FinSMEsRibometrix Raises $7.8M in FundingRibometrix, a biotechnology company based in Durham, N.C., raised $7.8 million in funding from existing investors including the Dementia Discovery Fund and Illumina Ventures to support its discovery platform development. Concurrently, the company appointed Dr. Mike Clayman as chairman of the board of directors.VC News DailyRibometrix Announces $7.8M in New FundingRibometrix, a North Carolina-based biotechnology company developing small molecule therapeutics that target RNA to treat human diseases, announced $7.8 million in additional funding from existing investors the Dementia Discovery Fund and Illumina Ventures. The company also appointed Mike Clayman, former co-founder and CEO of Flexion Therapeutics, as chairman of its board of directors. The funding will support continued development of Ribometrix's discovery platform, which uses 3D structural analysis to identify RNA-binding small molecules with therapeutic potential.FinSMEsRibometrix Raises $30M in Series A FundingRibometrix, a Durham-based biotech, raised $30M in Series A financing led by M Ventures. The company will use the funds to advance its RNA-targeting discovery platform and expand its team. Hakan Goker will join the board as non-executive director.